Indian Dr. Reddy's in Talks to Buy Haleon's Nicotinell, Sky News Reports
--Indian pharmaceutical group Dr. Reddy's Laboratories is in ongoing talks to buy the anti-smoking aid Nicotinell from Haleon, Sky News reports, citing unnamed sources.
--Financial details regarding how much Dr Reddy's might pay to Haleon--which was spun out of GSK and Pfizer's consumer-healthcare business--remain unclear, but it is unlikely to be as much as the $800 million suggested in a previous report, Sky News reports.
--The companies weren't immediately available for comment.
Full story: https://bit.ly/3HFrAOx
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
January 16, 2024 08:43 ET (13:43 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings, Is Coinbase Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy
-
Energy Transfer Earnings: M&A Drives Guidance Increase In Solid Quarter
-
The Best Healthcare Stocks to Buy
-
Going Into Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?